Skip to main content
    C

    Cardiff Oncology Inc (CRDF)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.85
    +0.12 (+16.75%)

    Market Cap: $56.49M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cardiff Oncology Inc (CRDF) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Cardiff Oncology (CRDF) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Cardiff Oncology reported EPS of -$0.12, above the -$0.14 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    +6.35%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 22, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.16
    Range-$0.21 - -$0.09
    9 analysts
    Revenue Consensus
    $85.00K
    RangeN/A
    9 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.13
    Range-$0.16 - -$0.09
    2 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.15+16.7%
    60d ago-$0.15+16.7%
    30d ago-$0.13+3.8%
    7d ago-$0.13+3.8%
    Current-$0.13
    Revenue Consensus
    $116.67K
    Range$50.00K - $200.00K
    3 analysts

    Next Report

    CRDF has an expected report date of Feb 22, 2027.

    CRDF Earnings Call

    The latest CRDF earnings call transcript on file is labeled 2024Q4.

    Read the 2024Q4 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CRDF beat 23, missed 12 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $171000, up 42.5% from $120000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.12-$0.14-$0.14 - -$0.12+14.29%BeatN/A44 up, 0 downNov 12, 2026$171000
    Jun 30, 2026-$0.14-$0.17N/A+17.65%BeatN/A60 up, 5 downAug 11, 2026$104000
    Mar 31, 2026-$0.18-$0.12-$0.16 - -$0.11-50.00%MissN/A53 up, 0 downMay 14, 2026$41000
    Dec 31, 2025-$0.11-$0.20-$0.26 - -$0.18+45.00%BeatN/A62 up, 0 downFeb 24, 2026$243000
    Sep 30, 2025-$0.17-$0.21-$0.23 - -$0.19+19.05%BeatN/A61 up, 3 downNov 6, 2025$120000
    Jun 30, 2025-$0.21-$0.20-$0.22 - -$0.16-5.00%MissN/A60 up, 1 downJul 29, 2025$121000
    Mar 31, 2025-$0.20-$0.19-$0.23 - -$0.14-5.26%MissN/A5N/AMay 8, 2025$109000
    Dec 31, 2024-$0.21-$0.25-$0.29 - -$0.20+15.15%BeatN/A41 up, 0 downFeb 27, 2025$150000
    Sep 30, 2024-$0.25-$0.27-$0.29 - -$0.26+7.41%BeatN/A50 up, 0 downNov 7, 2024$165000
    Jun 30, 2024-$0.26-$0.25N/A-4.00%MissN/AN/A0 up, 0 downAug 8, 2024$163000
    Mar 31, 2024-$0.22-$0.25-$0.27 - -$0.23+12.00%BeatN/A40 up, 0 downMay 2, 2024$205000
    Dec 31, 2023-$0.21-$0.28-$0.29 - -$0.27+25.00%BeatN/A40 up, 0 downFeb 29, 2024$156000
    Sep 30, 2023-$0.22-$0.29-$0.32 - -$0.27+24.14%BeatN/A50 up, 0 downNov 2, 2023$141000
    Jun 30, 2023-$0.25-$0.25-$0.29 - -$0.230.00%In lineN/A50 up, 0 downAug 9, 2023$108000
    Mar 31, 2023-$0.25-$0.22-$0.25 - -$0.21-13.64%MissN/A50 up, 0 downMay 4, 2023$83000
    Dec 31, 2022-$0.20-$0.23-$0.30 - -$0.20+13.04%BeatN/A40 up, 0 downMar 2, 2023$128000
    Sep 30, 2022-$0.20-$0.24-$0.29 - -$0.24+16.67%BeatN/A50 up, 0 downNov 3, 2022$93000
    Jun 30, 2022-$0.24-$0.25N/A+4.00%BeatN/AN/A0 up, 0 downAug 4, 2022$91000
    Mar 31, 2022-$0.25-$0.23-$0.25 - -$0.21-8.70%MissN/A60 up, 0 downMay 5, 2022$74000
    Dec 31, 2021-$0.23-$0.17-$0.19 - -$0.14-35.29%MissN/A6N/AFeb 24, 2022$133000
    Sep 30, 2021-$0.17-$0.17-$0.19 - -$0.150.00%In lineN/A41 up, 0 downNov 4, 2021$86000
    Jun 30, 2021-$0.17-$0.15-$0.17 - -$0.12-13.33%MissN/A4N/AAug 5, 2021$68000
    Mar 31, 2021-$0.14-$0.15-$0.17 - -$0.12+6.67%BeatN/A4N/AMay 6, 2021$72000
    Dec 31, 2020-$0.08-$0.14-$0.15 - -$0.12+42.86%BeatN/A4N/AFeb 25, 2021$119000
    Sep 30, 2020-$0.19-$0.19-$0.20 - -$0.170.00%In lineN/A3N/ANov 5, 2020$136000
    Jun 30, 2020-$0.51-$0.24-$0.24 - -$0.24-112.50%MissN/A1N/AAug 11, 2020$43000
    Mar 31, 2020-$0.41-$0.41N/A0.00%In lineN/AN/AN/AMay 7, 2020$68000
    Dec 31, 2019-$0.51-$0.51N/A0.00%In lineN/AN/AN/AFeb 27, 2020$92576
    Sep 30, 2019-$0.71-$0.84N/A+15.48%BeatN/AN/AN/ANov 7, 2019$51687
    Jun 30, 2019-$0.78-$1.02N/A+23.53%BeatN/AN/AN/AAug 8, 2019$38348
    Mar 31, 2019-$1.02-$1.07N/A+4.67%BeatN/AN/AN/AMay 7, 2019$62021
    Dec 31, 2018-$1.09-$1.05N/A-3.81%MissN/AN/AN/AMar 6, 2019$78015
    Sep 30, 2018-$1.08-$1.98N/A+45.45%BeatN/AN/AN/ANov 7, 2018$88361
    Jun 30, 2018-$1.80-$1.98N/A+9.09%BeatN/AN/AN/AAug 3, 2018$111813
    Mar 31, 2018-$6.06-$5.76N/A-5.21%MissN/AN/AN/AMay 8, 2018$100136
    Dec 31, 2017-$4.32-$9.00N/A+52.00%BeatN/AN/AN/AFeb 26, 2018$185026
    Sep 30, 2017-$8.64-$17.28N/A+50.00%BeatN/AN/AN/ANov 9, 2017$123329
    Jun 30, 2017-$9.82-$23.04N/A+57.38%BeatN/AN/AN/AAug 9, 2017$102011
    Mar 31, 2017-$19.44-$17.28N/A-12.50%MissN/AN/AN/AMay 10, 2017$95038
    Dec 31, 2016-$22.44-$23.04N/A+2.60%BeatN/AN/AN/AMar 15, 2017$68072
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.69, after -$0.94 the year before. It was -$97.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.69N/A
    Dec 31, 2024-$0.94N/A
    Dec 31, 2023-$0.93N/A
    Dec 31, 2022-$0.89N/A
    Dec 31, 2021-$0.71N/A
    Dec 31, 2020-$1.19N/A
    Dec 31, 2019-$3.02N/A
    Dec 31, 2018-$10.03N/A
    Dec 31, 2017-$42.22N/A
    Dec 31, 2016-$97.65N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2024Q4 for the period ended Dec 31, 2024, runs about 2,800 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q4Dec 31, 20242,8079
    2024Q2Jun 30, 20242,1726

    2024Q4 Earnings Call

    Opening remarks

    Kiki Patel Speaker Thank you, operator. Joining us on the call today from Cardiff Oncology, our Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine. During this conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results, and the timing of data readouts for onvansertib clinical trials. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to differ from these statements include factors the company described in the section titled Risk Factors in its annual report on Form 10-K filed with the SEC for the year ended December 31, 2024. Cardiff Oncology undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I turn the call over to Chief Executive Officer, Mark Erlander. Mark?

    Mark Erlander CEO Thank you, Kiki, and good afternoon, everyone, and thank you for joining our business update conference call. The fourth quarter of 2024 was significant for Cardiff Oncology. On December 10, we released initial data from our ongoing CRDF-004 trial in first-line RAS-Mutated Metastatic Colorectal Cancer or mCRC, which we believe was highly encouraging and served as a basis for us to successfully complete a $40 million capital raise. On today's call, we will address four topics. First, we will briefly review the data we previously released from our lead program in mCRC and then provide an update on CRDF-004 enrollment activity and our registrational plans for onvansertib. Second, we will discuss our intellectual property strategy including the advances made in 2024 and what we expect for 2025. Third, we will share highlights from two preclinical posters we presented at the San Antonio Breast Cancer Symposium in December. Finally, we will discuss our financial position that we disclosed today in our Form 10-K filing. I begin with a review of the previously disclosed data from CRDF-004, which is our ongoing randomized Phase 2 trial in first-line RAS-mutated mCRC evaluating two dose levels of onvansertib combined with current standard of care regimens FOLFIRI or FOLFOX plus bevacizumab versus standard of care alone. In December, we released an initial data set as of November 26, 2024 for the first 30 patients on the trial. Overall, we were pleased with the efficacy signal observed in the trial. First, as of the data cutoff date, patients on the 30 mg dose of onvansertib demonstrated a 64% ORR compared to a 33% ORR in the control arm.

    Frequently Asked Questions About CRDF

    When is Cardiff Oncology's next earnings date?

    Cardiff Oncology's next earnings report is expected for Feb 22, 2027.

    Did CRDF beat earnings estimates last quarter?

    Yes. Cardiff Oncology reported EPS of -$0.12 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 14.29% surprise.

    What EPS do analysts expect from CRDF next quarter?

    The consensus EPS estimate for Cardiff Oncology for the quarter ending Dec 31, 2026 is -$0.16 from 9 analysts, with estimates from -$0.21 to -$0.09.

    How often does CRDF beat earnings estimates?

    Cardiff Oncology beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +6.36%.